These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2910559)

  • 1. Fibronectin is unsuitable as a tumor marker in pleural effusions.
    Delpuech P; Desch G; Fructus F
    Clin Chem; 1989 Jan; 35(1):166-8. PubMed ID: 2910559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibronectin concentrations in pleural effusions of patients with malignant and non-malignant diseases.
    Siri A; Carnemolla B; Raffanti S; Castellani P; Balzano E; Zardi L
    Cancer Lett; 1984 Feb; 22(1):1-9. PubMed ID: 6421478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers.
    Zennaro L; Vanzani P; Nicolè L; Cappellesso R; Fassina A
    Cancer Cytopathol; 2017 May; 125(5):341-348. PubMed ID: 28140518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The etiology of pleural effusions in an area with high incidence of tuberculosis.
    Valdés L; Alvarez D; Valle JM; Pose A; San José E
    Chest; 1996 Jan; 109(1):158-62. PubMed ID: 8549179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischemia modified albumin in the differential diagnosis of pleural effusions.
    Dikensoy O; Celik N; Kul S; Gogebakan B; Bayram H; Light RW
    Respir Med; 2011 Nov; 105(11):1712-7. PubMed ID: 21843931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the value of fibronectin as a tumour marker in malignant pleural mesothelioma.
    Emri S; Ustündağ Y; Budak T; Karakoca Y; Ozdemir O
    Monaldi Arch Chest Dis; 1997 Aug; 52(4):335-8. PubMed ID: 9401361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of sialic acid in malignant pleural effusions.
    Imecik O; Ozer F
    Chest; 1992 Dec; 102(6):1819-22. PubMed ID: 1446495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of soluble interleukin 2 receptor in differentiating tuberculous and carcinomatous pleural effusions.
    Chang SC; Hsu YT; Chen YC; Lin CY
    Arch Intern Med; 1994 May; 154(10):1097-101. PubMed ID: 8185423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential role for nitric oxide pathway in tuberculous pleural effusion.
    Elgün S; Kaçmaz B; Durak I
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):339-43. PubMed ID: 15786901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentraxin-3: A novel biomarker for discriminating parapneumonic from other exudative effusions.
    Ozsu S; Abul Y; Mentese A; Bektas H; Uzun A; Ozlu T; Porcel JM
    Respirology; 2013 May; 18(4):657-62. PubMed ID: 23286371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin is upregulated in malignant and inflammatory pleural effusions.
    Moschos C; Porfiridis I; Psallidas I; Kollintza A; Stathopoulos GT; Papiris SA; Roussos C; Kalomenidis I
    Respirology; 2009 Jul; 14(5):716-22. PubMed ID: 19476604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion.
    Aoe K; Hiraki A; Maeda T; Murakami T; Yamazaki K; Sugi K; Takeyama H
    Chest; 2004 Oct; 126(4):1195-7. PubMed ID: 15486382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of pleural fluid N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases.
    Liao H; Na MJ; Dikensoy O; Lane KB; Randal B; Light RW
    Respirology; 2008 Jan; 13(1):53-7. PubMed ID: 18197911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of pleural fluid NT-pro brain natriuretic peptide (NT-proBNP) in patients with pleural effusions.
    Han CH; Choi JE; Chung JH
    Intern Med; 2008; 47(19):1669-74. PubMed ID: 18827414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibronectin in exudative pleural effusions.
    Klockars M; Pettersson T; Vartio T; Riska H; Vaheri A
    J Clin Pathol; 1982 Jul; 35(7):723-7. PubMed ID: 7096593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion.
    Rodríguez-Piñeiro AM; Blanco-Prieto S; Sánchez-Otero N; Rodríguez-Berrocal FJ; de la Cadena MP
    J Proteomics; 2010 Jun; 73(8):1511-22. PubMed ID: 20230924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of YKL-40 and MIP-1a proteins in exudates and transudates: biomarkers for differential diagnosis of pleural effusions? A pilot study.
    Adamidi T; Soulitzis N; Neofytou E; Zannetos S; Georgiou A; Benidis K; Papadopoulos A; Siafakas NM; Schiza SE
    BMC Pulm Med; 2015 Dec; 15():150. PubMed ID: 26620310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of lipid peroxidation and antioxidant enzymes in malignant (bronchogenic carcinoma) and non-malignant pleural effusions.
    Vanisree AJ; Shyamaladevi CS
    Indian J Cancer; 1999; 36(2-4):127-34. PubMed ID: 10921216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions.
    Ferrer J; Villarino MA; Encabo G; Felip E; Bermejo B; Vilà S; Orriols R
    Cancer; 1999 Oct; 86(8):1488-95. PubMed ID: 10526277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions.
    Park DS; Hwang KE; Shim H; Kim BR; Choi KH; Park SH; Park SD; Jeong ET; Kim HR
    Clin Exp Metastasis; 2012 Feb; 29(2):83-9. PubMed ID: 22045227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.